Determination of Regulatory Review Period for Purposes of Patent Extension; ELAHERE

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for patent extension for human biological product ELAHERE, as required by law. The FDA made this determination following a submission to the US Patent and Trademark Office (USPTO), Department of Commerce.